Roberto Ravazzolo

Prof. Dr. Roberto Ravazzolo

Università degli Studi di Genova, Genova, Italy

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2006 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
ADAndrea D'OSualdo
Andrea D'OSualdo
FFFrancesca Ferlito
Francesca Ferlito
IPIgnazia Prigione
Ignazia Prigione
LOLaura Obici
Laura Obici
AMAntonella Meini
Antonella Meini
MGMarco Gattorno
Marco Gattorno
Objective: To explore tumor necrosis factor (TNF)–induced apoptosis in neutrophils from patients with TNF receptor–associated periodic syndrome (TRAPS) and to correlate the results with the different kinds of TNFRSF1A mutations.Methods: Two hundred sixty‐five patients with clinically suspected inherited autoinflammatory syndrome were screened for mutations of the TNFRSF1A gene. Neutrophils were isolated from heparinized blood by dextran sedimentation and incubated with and without cycloheximide (CHX) and TNFα. Cell apoptosis was assessed by human annexin V binding, and caspase 8 activation was assessed by flow cytometry.Results: Twenty‐one patients were found to carry a variant of the TNFRSF1A gene: 13 patients had an R92Q substitution, and 8 patients presented other missense substitutions, 1 splicing mutation, and 1 in‐frame interstitial deletion. Neutrophil stimulation with TNF and CHX was associated with induction of apoptosis in 12 normal controls and in 10 subjects with the R92Q mutation. Conversely, neutrophils from 8 TRAPS patients with mutations of cysteine or threonine residues or interstitial deletion did not show any induction of apoptosis after stimulation. The incidence of the R92Q mutation among patients with recurrent autoinflammatory syndromes was similar to that observed in the normal population.Conclusion: Resistance to TNF‐mediated apoptosis is a feature in TRAPS patients who have mutations of cysteine residues or interstitial deletion, and may play a pathogenic role. The R92Q mutation does not appear to be significantly associated with TRAPS.

1 July 2007 in Human Mutation
Verified
Journal Article
Closed access
PDF file
RBRenata Bocciardi
Renata Bocciardi
RGRoberto Giorda
Roberto Giorda
JBJens Buttgereit
Jens Buttgereit
SGStefania Gimelli
Stefania Gimelli
MDMaria Teresa Divizia
Maria Teresa Divizia
GGGiorgio Gimelli
Giorgio Gimelli
Longitudinal bone growth is determined by the process of endochondral ossification in the cartilaginous growth plate, which is located at both ends of vertebrae and long bones and involves many systemic hormones and local regulators. We report the molecular characterization of a de novo balanced t(2;7)(q37.1;q21.3) translocation in a young female with Marfanoid habitus and skeletal anomalies. The translocation was characterized by fluorescence in situ hybridization (FISH), checked for other abnormalities by array‐comparative genomic hybridization (CGH), and finally, the breakpoints were cloned, sequenced, and compared. Biochemical dosage was applied to study the possible mechanisms that may cause the proposita's phenotype. The breakpoint on chromosome 2 disrupts the hypothetical gene MGC42174 (HUGO‐approved symbol DIS3L2) and is located in the proximity of the NPPC gene coding for C‐type natriuretic peptide (CNP), a molecule that regulates endochondral bone growth. CNP plasma concentration was doubled in the proband compared to five normal controls, while NPPC was substantially overexpressed in her fibroblasts. A transgenic mouse generated to target NPPC overexpression in bone showed a phenotype highly reminiscent of the patient's phenotype. The breakpoint on chromosome 7 is localized proximally at about 75 kb from the COL1A2 gene. The COL1A2 allele on the derivative chromosome was strongly underexpressed in fibroblasts, but total collagen was not significantly different from controls. Several evidences support the conclusion that the proband's abnormal phenotype is associated with C‐type natriuretic peptide overexpression. Hum Mutat 28(7), 724–731, 2007.

1 October 2008 in European Journal of Human Genetics
Verified
Journal Article
Closed access
RBRenata Bocciardi
Renata Bocciardi
DBDomenico Bordo
Domenico Bordo
MDMarco Di Duca
Marco Di Duca
MRMaja Di Rocco
Maja Di Rocco
RRRoberto Ravazzolo
Roberto Ravazzolo

30 May 2014 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
CVCarlotta Maria Vaccari
Carlotta Maria Vaccari
MRMaria Victoria Romanini
Maria Victoria Romanini
Ilaria MusanteIlaria Musante
Ilaria Musante
ETElisa Tassano
Elisa Tassano
SGStefania Gimelli
Stefania Gimelli
APAldamaria PULITI
Aldamaria PULITI
Poland Syndrome (PS) is a rare disorder characterized by hypoplasia/aplasia of the pectoralis major muscle, variably associated with thoracic and upper limb anomalies. Familial recurrence has been reported indicating that PS could have a genetic basis, though the genetic mechanisms underlying PS development are still unknown.

Verified
Journal Article
Open access
PDF file
SCSerena Cappato
Serena Cappato
FGFrancesca Giacopelli
Francesca Giacopelli
RRRoberto Ravazzolo
Roberto Ravazzolo
RBRenata Bocciardi
Renata Bocciardi
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic condition characterized by progressive extra-skeletal ossification leading to cumulative and severe disability. FOP has an extremely variable and episodic course and can be induced by trauma, infections, iatrogenic harms, immunization or can occur in an unpredictable way, without any recognizable trigger. The causative gene is ACVR1, encoding the Alk-2 type I receptor for bone morphogenetic proteins (BMPs). The signaling is initiated by BMP binding to a receptor complex consisting of type I and II molecules and can proceed into the cell through two main pathways, a canonical, SMAD-dependent signaling and a p38-mediated cascade. Most FOP patients carry the recurrent R206H substitution in the receptor Glycine-Serine rich (GS) domain, whereas a few other mutations are responsible for a limited number of cases. Mutations cause a dysregulation of the downstream BMP-dependent pathway and make mutated ACVR1 responsive to a non-canonical ligand, Activin A. There is no etiologic treatment for FOP. However, many efforts are currently ongoing to find specific therapies targeting the receptor activity and the downstream aberrant pathway at different levels or targeting cellular components and/or processes that are important in modifying the local environment leading to bone neo-formation.

12 January 2009 in Clinical Immunology
Verified
Journal Article
Closed access
RMRenato Marciano
Renato Marciano
GDGiuseppe D'Annunzio
Giuseppe D'Annunzio
NMNicola Minuto
Nicola Minuto
LPLorenzo Pasquali
Lorenzo Pasquali
ASAndrea Santamaria
Andrea Santamaria
RLRenata Lorini
Renata Lorini